Siren Biotechnology Appointed Peter Bross to Advisory Board
The San Francisco-based firm recruited the former FDA oncology branch chief to guide its clinical program.
Updated on Oct. 14, 2026 in Biotech
Live Poll
Do you trust that new medical modalities developed by biotechnology companies will improve patient outcomes?
Siren Biotechnology has appointed Peter Bross to its Clinical and Scientific Advisory Board. Bross joins the firm with more than 25 years of regulatory experience gained during his tenure at the FDA.
Why it matters
The company is seeking specialized regulatory and clinical guidance to support the development of its therapeutic platform. Bross will provide expertise as the company prepares to move its lead candidate, SRN-101, into clinical execution.
Siren Biotechnology is currently advancing its SRN-101 Universal AAV Immuno-Gene Therapy candidate for recurrent high-grade glioma. The company is operating under two cleared Investigational New Drug applications for this program.
The players
Peter Bross
He is the former Chief of the Oncology Branch at the FDA's Center for Biologics Evaluation and Research who holds over 25 years of regulatory experience.
Siren Biotechnology
Based in San Francisco, this clinical-stage biotechnology company focuses on developing gene therapy candidates.
The details
Peter Bross previously served as the Chief of the Oncology Branch at the FDA's Center for Biologics Evaluation and Research. In his new role, he will advise on the clinical execution and regulatory foundation for the company's gene therapy platform.
Timeline
1999: Peter Bross joined the FDA.
October 14, 2026: Siren Biotechnology announced the appointment of Peter Bross.
The Tech Race
The appointment signals a strategic move to strengthen regulatory pathways for AAV Immuno-Gene Therapy, an emerging field in precision medicine. Siren Biotechnology aims to bridge the gap between initial research and human clinical trials by leveraging deep institutional knowledge from the FDA.
For patients and healthcare providers, this appointment indicates that the company is actively preparing to move its glioma therapy into clinical settings. Stakeholders should monitor future trial announcements for updates on potential treatment eligibility and timelines.
The takeaway
Bringing on former regulatory leaders is a common strategy for biotech firms looking to streamline their path to clinical trials. Investors and researchers typically view these high-level appointments as a sign of institutional focus on meeting federal safety and efficacy standards.
Further reading
For more on the local biotechnology sector, visit the San Francisco Biotech hub.
More information
To learn more about the company's ongoing research and programs, visit the Siren Biotechnology official website.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust that new medical modalities developed by biotechnology companies will improve patient outcomes?
